

**Golimumab Formulation**

Version 2.12      Revision Date: 23.02.2023      SDS Number: 26421-00024      Date of last issue: 13.02.2023  
Date of first issue: 29.10.2014

---

**SECTION 1. PRODUCT AND COMPANY IDENTIFICATION**

Product name : Golimumab Formulation

**Manufacturer or supplier's details**

Company : MSD

Address : Rua Coronel Bento Soares, 530  
Cruzeiro - Sao Paulo - Brazil CEP 12730-340

Telephone : 908-740-4000

Emergency telephone : 1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

**Recommended use of the chemical and restrictions on use**

Recommended use : Pharmaceutical

Restrictions on use :  
Not applicable

---

**SECTION 2. HAZARDS IDENTIFICATION****GHS Classification in accordance with ABNT NBR 14725 Standard**

Respiratory sensitization : Category 1

**GHS label elements in accordance with ABNT NBR 14725 Standard**

Hazard pictograms :



Signal Word : Danger

Hazard Statements : H334 May cause allergy or asthma symptoms or breathing difficulties if inhaled.

Precautionary Statements : **Response:**  
P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.  
P342 + P311 If experiencing respiratory symptoms: Call a POISON CENTER/ doctor.

**Other hazards which do not result in classification**

None known.

---

**SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS**

## Golimumab Formulation

Version 2.12      Revision Date: 23.02.2023      SDS Number: 26421-00024      Date of last issue: 13.02.2023  
 Date of first issue: 29.10.2014

Substance / Mixture : Mixture

### Components

Chemical name	CAS-No.	Classification	Concentration (% w/w)
Golimumab	476181-74-5	Respiratory sensitization, Category 1	>= 10 -< 20

### SECTION 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
 When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
 If not breathing, give artificial respiration.  
 If breathing is difficult, give oxygen.  
 Get medical attention.
- In case of skin contact : Wash with water and soap as a precaution.  
 Get medical attention if symptoms occur.
- In case of eye contact : Flush eyes with water as a precaution.  
 Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
 Get medical attention if symptoms occur.  
 Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : Excessive exposure may aggravate preexisting asthma and other respiratory disorders (e.g. emphysema, bronchitis, reactive airways dysfunction syndrome).  
 May cause allergy or asthma symptoms or breathing difficulties if inhaled.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### SECTION 5. FIRE-FIGHTING MEASURES

- Suitable extinguishing media : Water spray  
 Alcohol-resistant foam  
 Carbon dioxide (CO<sub>2</sub>)  
 Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
 Sulfur oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
 Use water spray to cool unopened containers.  
 Remove undamaged containers from fire area if it is safe to do so.

## Golimumab Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.02.2023
2.12	23.02.2023	26421-00024	Date of first issue: 29.10.2014

---

Special protective equipment for fire-fighters : Evacuate area.  
 In the event of fire, wear self-contained breathing apparatus.  
 Use personal protective equipment.

---

### SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
 Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

Environmental precautions : Avoid release to the environment.  
 Prevent further leakage or spillage if safe to do so.  
 Prevent spreading over a wide area (e.g., by containment or oil barriers).  
 Retain and dispose of contaminated wash water.  
 Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up : Soak up with inert absorbent material.  
 For large spills, provide diking or other appropriate containment to keep material from spreading. If diked material can be pumped, store recovered material in appropriate container.  
 Clean up remaining materials from spill with suitable absorbent.  
 Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
 Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

### SECTION 7. HANDLING AND STORAGE

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Avoid breathing mist or vapors.  
 Do not swallow.  
 Avoid contact with eyes.  
 Avoid prolonged or repeated contact with skin.  
 Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
 Keep container tightly closed.  
 Already sensitized individuals, and those susceptible to asthma, allergies, chronic or recurrent respiratory disease, should consult their physician regarding working with respiratory irritants or sensitizers.  
 Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place.

## Golimumab Formulation

Version 2.12      Revision Date: 23.02.2023      SDS Number: 26421-00024      Date of last issue: 13.02.2023  
 Date of first issue: 29.10.2014

Conditions for safe storage : When using do not eat, drink or smoke.  
 Wash contaminated clothing before re-use.  
 Keep in properly labeled containers.  
 Keep tightly closed.  
 Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:  
 Strong oxidizing agents  
 Gases

## SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

## Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Golimumab	476181-74-5	TWA	70 µg/m <sup>3</sup> (OEB 3)	Internal

**Engineering measures** : Ensure adequate ventilation, especially in confined areas.  
 Minimize workplace exposure concentrations.

**Personal protective equipment**

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration specific to place of work. Breakthrough time is not determined for the product. Change gloves often!  
 For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Eye protection : Wear the following personal protective equipment:  
 Safety glasses

Skin and body protection : Skin should be washed after contact.

## SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : Aqueous solution

Color : opalescent

Odor : No data available

Odor Threshold : No data available

pH : 5,5

Melting point/freezing point : No data available

**Golimumab Formulation**

Version 2.12      Revision Date: 23.02.2023      SDS Number: 26421-00024      Date of last issue: 13.02.2023  
Date of first issue: 29.10.2014

---

Initial boiling point and boiling range : No data available

Flash point : No data available

Evaporation rate : No data available

Flammability (solid, gas) : Not applicable

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapor pressure : No data available

Relative vapor density : No data available

Relative density : No data available

Solubility(ies)  
Water solubility : soluble

Partition coefficient: n-octanol/water : No data available

Autoignition temperature : No data available

Decomposition temperature : No data available

Viscosity  
Viscosity, kinematic : No data available

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Molecular weight : No data available

Particle size : No data available

---

**SECTION 10. STABILITY AND REACTIVITY**

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition : No hazardous decomposition products are known.

**Golimumab Formulation**

Version 2.12      Revision Date: 23.02.2023      SDS Number: 26421-00024      Date of last issue: 13.02.2023  
Date of first issue: 29.10.2014

---

products

---

**SECTION 11. TOXICOLOGICAL INFORMATION**

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

**Acute toxicity**

Not classified based on available information.

**Skin corrosion/irritation**

Not classified based on available information.

**Serious eye damage/eye irritation**

Not classified based on available information.

**Respiratory or skin sensitization****Skin sensitization**

Not classified based on available information.

**Respiratory sensitization**

May cause allergy or asthma symptoms or breathing difficulties if inhaled.

**Components:****Golimumab:**

Routes of exposure : Inhalation  
Assessment : May cause sensitization by inhalation.

**Germ cell mutagenicity**

Not classified based on available information.

**Carcinogenicity**

Not classified based on available information.

**Reproductive toxicity**

Not classified based on available information.

**Components:****Golimumab:**

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Mouse, male  
Application Route: Intravenous injection  
Fertility: NOAEL Parent: 40 mg/kg body weight

Test Type: Fertility/early embryonic development  
Species: Mouse, female  
Application Route: Intravenous injection  
Fertility: NOAEL Parent: 40 mg/kg body weight

Effects on fetal development : Test Type: Embryo-fetal development  
Species: Monkey  
Teratogenicity: NOAEL: 100 mg/kg body weight

**Golimumab Formulation**

Version 2.12      Revision Date: 23.02.2023      SDS Number: 26421-00024      Date of last issue: 13.02.2023  
Date of first issue: 29.10.2014

---

Embryo-fetal toxicity.: NOAEL: 100 mg/kg body weight

Test Type: Development  
Species: Monkey  
Developmental Toxicity: NOAEL F1: 50 mg/kg body weight

Test Type: Embryo-fetal development  
Species: Mouse  
Application Route: Intravenous injection  
Teratogenicity: NOAEL: 40 mg/kg body weight  
Embryo-fetal toxicity.: NOAEL: 40 mg/kg body weight  
Result: negative, No effects on fetal development.

**STOT-single exposure**

Not classified based on available information.

**STOT-repeated exposure**

Not classified based on available information.

**Repeated dose toxicity****Components:****Golimumab:**

Species : Monkey  
NOAEL : 50 mg/kg  
Application Route : Intravenous  
Exposure time : 6 Months  
Number of exposures : Intermittent

Species : Monkey  
NOAEL : 25 mg/kg  
Application Route : Subcutaneous  
Exposure time : 6 Months

Species : Mouse  
NOAEL : 40 mg/kg  
Application Route : Intravenous

**Aspiration toxicity**

Not classified based on available information.

**Experience with human exposure****Components:****Golimumab:**

Inhalation : Symptoms: mild infections, upper respiratory tract infection, viral infections, bronchitis, sinusitis, fungal infections

## Golimumab Formulation

Version 2.12      Revision Date: 23.02.2023      SDS Number: 26421-00024      Date of last issue: 13.02.2023  
Date of first issue: 29.10.2014

---

### SECTION 12. ECOLOGICAL INFORMATION

#### Ecotoxicity

##### Components:

##### Golimumab:

#### Ecotoxicology Assessment

Acute aquatic toxicity : No data available

Chronic aquatic toxicity : No data available

#### Persistence and degradability

No data available

#### Bioaccumulative potential

No data available

#### Mobility in soil

No data available

#### Other adverse effects

No data available

---

### SECTION 13. DISPOSAL CONSIDERATIONS

#### Disposal methods

Waste from residues : Dispose of in accordance with local regulations.  
Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

---

### SECTION 14. TRANSPORT INFORMATION

#### International Regulations

##### UNRTDG

Not regulated as a dangerous good

##### IATA-DGR

Not regulated as a dangerous good

##### IMDG-Code

Not regulated as a dangerous good

#### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

#### Domestic regulation

##### ANTT

Not regulated as a dangerous good

---



**Golimumab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.02.2023
2.12	23.02.2023	26421-00024	Date of first issue: 29.10.2014

---

**Special precautions for user**

Not applicable

**SECTION 15. REGULATORY INFORMATION****Safety, health and environmental regulations/legislation specific for the substance or mixture**

National List of Carcinogenic Agents for Humans - (LINACH) : Not applicable

Brazil. List of chemicals controlled by the Federal Police : Not applicable

**The ingredients of this product are reported in the following inventories:**

AICS : not determined

DSL : not determined

IECSC : not determined

**SECTION 16. OTHER INFORMATION**Revision Date : 23.02.2023  
Date format : dd.mm.yyyy**Further information**Sources of key data used to compile the Material Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>**Full text of other abbreviations**

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect

**Golimumab Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 13.02.2023
2.12	23.02.2023	26421-00024	Date of first issue: 29.10.2014

---

Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECL - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

BR / Z8